Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies

Abstract

Selective combinations of these leukemia-specific BsAb offer the potential to overcome tumor heterogeneity or clonal escape in the modern era of antibody-based T cell-driven immunotherapy.